ODAC Gives Thumbs Up To Affymax' Peginesatide
By Marie Powers
Thursday, December 8, 2011
After an afternoon of vigorous debate, members of the Oncologic Drugs Advisory Committee (ODAC) endorsed, by a 15-1 margin, the benefit/risk profile for peginesatide injection to treat anemia associated with chronic kidney disease (CKD) in adult patients on dialysis.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.